Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 57,180 shares of common stock in open-market transactions between April 14 and April 16, 2026, at an average price of approximately $14.45 per share, totaling around $826,000. This sale reduced her direct holdings by 12.29%, leaving her with 408,160 shares and 148,770 options. Despite the sale, her ongoing economic exposure remains significant. Adaptive Biotechnologies continues to grow, particularly in its minimal residual disease monitoring services, which saw a 46% revenue increase last year and received expanded Medicare coverage. The company’s market capitalization stands at $2.23 billion, reflecting its strategic partnerships and proprietary technology in the biotech space.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/04/18/should-you-sell-adaptive-biotechnologies-adpt-after-its-president-and-coo-sold-57-000-shares/
